THREAD Enriches Its Platform with CureClick to Accelerate Enrollment, Improve Diversity and Enhance the Patient Experience in Decentralized Clinical Trials
CARY, N.C., April 19, 2022 /PRNewswire/ -- THREAD®, a leading technology and consulting service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), today announced that it has acquired CureClick. Headquartered in Costa Mesa, Calif., CureClick offers the world's first proprietary crowdsourcing platform designed exclusively to accelerate awareness and participation in clinical research. CureClick follows THREAD's recent acquisitions of Modus Outcomes and inVibe, positioning THREAD as the industry's leading patient-centric provider of DCTs.
CureClick partners with a variety of organizations who are committed to advancing medical research through clinical trials. From the patient communities, and advocacy groups who are driving the dialogue about the value of medical research, to the CROs, Pharmaceutical companies, and agencies who sponsor, and promote clinical trials for promising medications, CureClick is able to simply, and effectively integrate with all partners.
We know patients see their online communities as lifelines, as one-stop-shops for the latest news, and information about their health condition. We want to engage with them on their terms by partnering with the community leaders, and advocates they trust.